Filtered By:
Infectious Disease: Coronavirus
This page shows you your search results in order of date.
Order by Relevance | Date
Total 118 results found since Jan 2013.
Evaluating how cationic lipid affects mRNA-LNP physical properties and biodistribution
Eur J Pharm Biopharm. 2023 Aug 12:S0939-6411(23)00205-9. doi: 10.1016/j.ejpb.2023.08.002. Online ahead of print.ABSTRACTRNA therapeutics represents a powerful strategy for diseases where other approaches have failed, especially given the recent successes of mRNA vaccines against the coronavirus disease 2019 (COVID-19) and small interfering (siRNA) therapeutics. However, further developments are still required to reduce toxicity, improve stability and biodistribution of mRNA-LNPs (lipid nanoparticles). Here, we show a rational combinatorial approach to select the best formulation based on a new cationic lipid molecule (IM21...
Source: European Journal of Pharmaceutics and Biopharmaceutics - August 14, 2023 Category: Drugs & Pharmacology Authors: Claire Gu éguen Thibaut Ben Chimol Margaux Briand Kassandra Renaud M élodie Seiler Morgane Ziesel Patrick Erbacher Malik Hellal Source Type: research
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a respiratory virus that causes COVID-19 disease, with an estimated global mortality of approximately 2%. While global response strategies, which are predominantly reliant on regular vaccinations, have shifted from zero COVID to living with COVID, there is a distinct lack of broad-spectrum direct acting antiviral therapies that maintain efficacy across evolving SARS-CoV-2 variants of concern. This is of most concern for immunocompromised and immunosuppressed ...
Source: Antiviral Research - July 21, 2023 Category: Virology Authors: Ellen Bowden-Reid Scott Ledger Yuan Zhang Francesca Di Giallonardo Anupriya Aggarwal Alberto Ospina Stella Anouschka Akerman Vanessa Milogiannakis Gregory Walker William Rawlinson Stuart Turville Anthony D Kelleher Chantelle Ahlenstiel Source Type: research
Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection
J Microbiol Immunol Infect. 2023 Mar 8:S1684-1182(23)00068-3. doi: 10.1016/j.jmii.2023.02.010. Online ahead of print.ABSTRACTRNA interference (RNAi) is an emerging and promising therapy for a wide range of respiratory viral infections. This highly specific suppression can be achieved by the introduction of short-interfering RNA (siRNA) into mammalian systems, resulting in the effective reduction of viral load. Unfortunately, this has been hindered by the lack of a good delivery system, especially via the intranasal (IN) route. Here, we have developed an IN siRNA encapsulated lipid nanoparticle (LNP) in vivo delivery system...
Source: Journal of Microbiology, Immunology, and Infection - March 18, 2023 Category: Microbiology Authors: Aroon Supramaniam Yaman Tayyar Daniel T W Clarke Gabrielle Kelly Dhruba Acharya Kevin V Morris Nigel A J McMillan Adi Idris Source Type: research
Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).PMID:36730646 | DOI:10.1165/rcmb.2022-0331OC
Source: Am J Respir Cell Mol... - February 2, 2023 Category: Respiratory Medicine Authors: Joseph S Bednash Finny Johns Daniela Farkas Ajit Elhance Jessica Adair Kirstin Cress Jacob S Yount Adam D Kenney James D Londino Rama K Mallampalli Source Type: research
